196 related articles for article (PubMed ID: 17714031)
1. Talabostat.
Cunningham CC
Expert Opin Investig Drugs; 2007 Sep; 16(9):1459-65. PubMed ID: 17714031
[TBL] [Abstract][Full Text] [Related]
2. Molecule of the month. Talabostat.
Drug News Perspect; 2006 Jun; 19(5):299. PubMed ID: 16941051
[No Abstract] [Full Text] [Related]
3. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.
Adams S; Miller GT; Jesson MI; Watanabe T; Jones B; Wallner BP
Cancer Res; 2004 Aug; 64(15):5471-80. PubMed ID: 15289357
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer.
Eager RM; Cunningham CC; Senzer N; Richards DA; Raju RN; Jones B; Uprichard M; Nemunaitis J
Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):464-72. PubMed ID: 19501491
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies.
Jones B; Adams S; Miller GT; Jesson MI; Watanabe T; Wallner BP
Blood; 2003 Sep; 102(5):1641-8. PubMed ID: 12738665
[TBL] [Abstract][Full Text] [Related]
6. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
7. Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides.
Coutts SJ; Kelly TA; Snow RJ; Kennedy CA; Barton RW; Adams J; Krolikowski DA; Freeman DM; Campbell SJ; Ksiazek JF; Bachovchin WW
J Med Chem; 1996 May; 39(10):2087-94. PubMed ID: 8642568
[TBL] [Abstract][Full Text] [Related]
8. AE-941 (AEterna).
Dredge K
Curr Opin Investig Drugs; 2004 Jun; 5(6):668-77. PubMed ID: 15242256
[TBL] [Abstract][Full Text] [Related]
9. 4-Substituted boro-proline dipeptides: synthesis, characterization, and dipeptidyl peptidase IV, 8, and 9 activities.
Wu W; Liu Y; Milo LJ; Shu Y; Zhao P; Li Y; Woznica I; Yu G; Sanford DG; Zhou Y; Poplawski SE; Connolly BA; Sudmeier JL; Bachovchin WW; Lai JH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5536-40. PubMed ID: 22853995
[TBL] [Abstract][Full Text] [Related]
10. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis.
Okondo MC; Johnson DC; Sridharan R; Go EB; Chui AJ; Wang MS; Poplawski SE; Wu W; Liu Y; Lai JH; Sanford DG; Arciprete MO; Golub TR; Bachovchin WW; Bachovchin DA
Nat Chem Biol; 2017 Jan; 13(1):46-53. PubMed ID: 27820798
[TBL] [Abstract][Full Text] [Related]
11. CYC-202 Cyclacel.
Guzi T
Curr Opin Investig Drugs; 2004 Dec; 5(12):1311-8. PubMed ID: 15648953
[TBL] [Abstract][Full Text] [Related]
12. MS-209 Schering.
Robert J
Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase inhibition: Paralyzing the cell's master switches.
Klein-Szanto AJ; Bassi DE
Biochem Pharmacol; 2017 Sep; 140():8-15. PubMed ID: 28456517
[TBL] [Abstract][Full Text] [Related]
14. Su-11248 Sugen.
Sakamoto KM
Curr Opin Investig Drugs; 2004 Dec; 5(12):1329-39. PubMed ID: 15648955
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors.
Huan Y; Jiang Q; Liu JL; Shen ZF
J Pharmacol Toxicol Methods; 2015; 71():8-12. PubMed ID: 25464020
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.
Van der Veken P; De Meester I; Dubois V; Soroka A; Van Goethem S; Maes MB; Brandt I; Lambeir AM; Chen X; Haemers A; Scharpé S; Augustyns K
Bioorg Med Chem Lett; 2008 Jul; 18(14):4154-8. PubMed ID: 18556199
[TBL] [Abstract][Full Text] [Related]
17. Epothilone D (Kosan/Roche).
Kolman A
Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function.
Flentke GR; Munoz E; Huber BT; Plaut AG; Kettner CA; Bachovchin WW
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1556-9. PubMed ID: 1671716
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy.
Nemunaitis J; Vukelja SJ; Richards D; Cunningham C; Senzer N; Nugent J; Duncan H; Jones B; Haltom E; Uprichard MJ
Cancer Invest; 2006 Oct; 24(6):553-61. PubMed ID: 16982458
[TBL] [Abstract][Full Text] [Related]
20. MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect.
Fuchs SY
Pigment Cell Melanoma Res; 2008 Feb; 21(1):9-10. PubMed ID: 18353138
[No Abstract] [Full Text] [Related]
[Next] [New Search]
